On Feb. 10, 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem cell-derived cancer immunotherapies.

Notch was founded in 2018 by Sunnybrook Research Institute and the University of Toronto, in conjunction with Toronto Innovation Acceleration Partners and the Centre for Commercialization of Regenerative Medicine in Toronto.